Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells

Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease

(2011) Motoko Koyama et al.   NATURE MEDICINE

Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

(2010) V. Dardalhon et al.   JOURNAL OF IMMUNOLOGY

TIM-3: A Novel Regulatory Molecule of Alloimmune Activation

(2010) O. Boenisch et al.   JOURNAL OF IMMUNOLOGY

TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines

(2009) William D. Hastings et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Galectin-9 Significantly Prolongs the Survival of Fully Mismatched Cardiac Allografts in Mice

(2009) Wentao He et al.   TRANSPLANTATION

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

(2008) R. Nishimura et al.   BLOOD

Activation of Tim-3–Galectin-9 pathway improves survival of fully allogeneic skin grafts

(2008) Feng Wang et al.   TRANSPLANT IMMUNOLOGY

In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFβ, but has no immediate effect on Foxp3

(2008) Poorni A. D. S. Muthukumarana et al.   TRANSPLANT INTERNATIONAL

Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality

(2007) L. K. Jasperson et al.   BLOOD